Biogen’s Aduhelm rollout goes from bad to worse
pharmaphorum
OCTOBER 21, 2021
Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. The slow roll out of Aduhelm raises pressure on Biogen to get the most out of Vumerity and other drugs like Sage Therapeutics-partnered antidepressant zuranolone, which is due to be filed next year.
Let's personalize your content